This is a preview of subscription content, log in via an institution to check access.
References
Vitti R, et al. Budgetary Impact of Intravitreal Aflibercept Injection (Iai) in Treating Neovascular Age-Related Macular Degeneration in a Us Health Plan of Adults Ages 65 Years and Older. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS5, 18 May 2013.
Vitti R, et al. Cost-Effectiveness of Intravitreal Aflibercept Injection (Iai) in Treating Neovascular Age-Related Macular Degeneration in the Us. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS10, 18 May 2013.
Additional information
* Both studies were funded by Regeneron Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Intravitreal aflibercept cost effective for wet AMD. PharmacoEcon Outcomes News 680, 7 (2013). https://doi.org/10.1007/s40274-013-0468-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0468-5